SCHEMBL957161

SCHEMBL957161

Cc1ccc(S(=O)(=O)NC(=O)Nc2nc(C)cs2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
FBP1 P09467 1/20 0.58
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 3/20 0.55
RAB9A P51151 3/20 0.55
MEN1 O00255 2/20 0.55
NPC1 O15118 1/20 0.55
GAA P10253 1/20 0.55
LMNA P02545 4/20 0.55
CA12 O43570 2/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
CA5A P35218 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA13 Q8N1Q1 2/20 0.52
CA14 Q9ULX7 2/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465664 0.80 ALDH1A1 (0.66) KDM4EFBP1CA1CA2KMT2A
SCHEMBL10465721 0.79 ALDH1A1 (0.50) KDM4EFBP1CA1CA2KMT2A
SCHEMBL958370 0.79 FBP1 (0.60) KDM4EFBP1CA1CA2KMT2A
SCHEMBL9720507 0.78 CA1 (0.60) KDM4EFBP1CA1CA2KMT2A
SCHEMBL10816647 0.77 RAB9A (0.71) KDM4EKMT2AALDH1A1RAB9AMEN1
SCHEMBL9720508 0.77 CA1 (0.73) KDM4EFBP1CA1CA2KMT2A
SCHEMBL6465229 0.76 KDM4E (0.63) KDM4ECA1CA2KMT2AALDH1A1
SCHEMBL29471326 0.76 ALDH1A1 (0.72) KDM4EKMT2AALDH1A1RAB9AMEN1
SCHEMBL10798732 0.76 MAPT (0.62) KDM4EKMT2AALDH1A1RAB9AMEN1
SCHEMBL5184740 0.75 LMNA (0.69) KDM4ECA1CA2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US claimed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP claimed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO claimed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US claimed
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US disclosed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP disclosed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents FBP1, PFKFB1, PFKFB3 KDM4E 1403/4885FBP1 1/4885CA1 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.